The company had posted a net profit of Rs 481.60 crore for the corresponding period of previous fiscal, it said in a filing to the BSE.
Consolidated net income of the company also rose to Rs 3,870.44 crore for the quarter from Rs 3,480.90 crore in the same period year ago.
For the full fiscal year, consolidated net profit rose to Rs 2,217.86 crore from Rs 2,151.20 crore year ago.
In a separate filing, Dr Reddy's Laboratories said the Board has recommended a final dividend of Rs 20 (400 per cent) per equity share of Rs 5 face value, for the financial year.
Shares of the drugmaker were trading at Rs 3,480 per scrip, up 3.51 per cent from its previous close in afternoon trade on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%